The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis

REFERENCES

1. 1.↵
   1. de Groot K,
   2. Harper L,
   3. Jayne DR,
   4. Flores Suarez LF,
   5. Gregorini G,
   6. Gross WL,
   7. et al.

   Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670–80.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. De Groot K,
   2. Rasmussen N,
   3. Bacon PA,
   4. Tervaert JW,
   5. Feighery C,
   6. Gregorini G,
   7. et al.

   Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461–9.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Jayne D,
   2. Rasmussen N,
   3. Andrassy K,
   4. Bacon P,
   5. Tervaert JW,
   6. Dadoniene J,
   7. et al.

   A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36–44.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. WGET Research Group

   . Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 2005;352:351–61.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Jayne DR,
   2. Gaskin G,
   3. Rasmussen N,
   4. Abramowicz D,
   5. Ferrario F,
   6. Guillevin L,
   7. et al.

   Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180–8.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Jones RB,
   2. Tervaert JW,
   3. Hauser T,
   4. Luqmani R,
   5. Morgan MD,
   6. Peh CA,
   7. et al.

   Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211–20.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Stone JH,
   2. Merkel PA,
   3. Spiera R,
   4. Seo P,
   5. Langford CA,
   6. Hoffman GS,
   7. et al.

   Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221–32.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Merkel PA,
   2. Seo P,
   3. Aries P,
   4. Neogi T,
   5. Villa-Forte A,
   6. Boers M,
   7. et al.

   Current status of outcome measures in vasculitis: focus on Wegener’s granulomatosis and microscopic polyangiitis. Report from OMERACT 7. J Rheumatol 2005;32:2488–95.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Seo P,
   2. Luqmani RA,
   3. Flossmann O,
   4. Hellmich B,
   5. Herlyn K,
   6. Hoffman GS,
   7. et al.

   The future of damage assessment in vasculitis. J Rheumatol 2007;34:1357–71.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Merkel PA,
    2. Herlyn K,
    3. Mahr AD,
    4. Neogi T,
    5. Seo P,
    6. Walsh M,
    7. et al.

    Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9. J Rheumatol 2009;36:2362–8.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Tugwell P,
    2. Boers M,
    3. Brooks P,
    4. Simon L,
    5. Strand V,
    6. Idzerda L

    . OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials 2007;8:38.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Boers M,
    2. Brooks P,
    3. Strand CV,
    4. Tugwell P

    . The OMERACT filter for outcome measures in rheumatology. J Rheumatol 1998;25:198–9.

    OpenUrlPubMed
13. 13.↵
    1. de Groot K,
    2. Gross WL,
    3. Herlyn K,
    4. Reinhold-Keller E

    . Development and validation of a disease extent index for Wegener’s granulomatosis. Clin Nephrol 2001;55:31–8.

    OpenUrlPubMed
14. 14.↵
    1. Guillevin L,
    2. Lhote F,
    3. Gayraud M,
    4. Cohen P,
    5. Jarrousse B,
    6. Lortholary O,
    7. et al.

    Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996;75:17–28.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Whiting-O’Keefe QE,
    2. Stone JH,
    3. Hellmann DB

    . Validity of a vasculitis activity index for systemic necrotizing vasculitis. Arthritis Rheum 1999;42:2365–71.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Luqmani RA,
    2. Bacon PA,
    3. Moots RJ,
    4. Janssen BA,
    5. Pall A,
    6. Emery P,
    7. et al.

    Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671–8.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Stone JH,
    2. Hoffman GS,
    3. Merkel PA,
    4. Min YI,
    5. Uhlfelder ML,
    6. Hellmann DB,
    7. et al.

    A disease-specific activity index for Wegener’s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001;44:912–20.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Mukhtyar C,
    2. Lee R,
    3. Brown D,
    4. Carruthers D,
    5. Dasgupta B,
    6. Dubey S,
    7. et al.

    Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009;68:1827–32.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Luqmani RA,
    2. Exley AR,
    3. Kitas GD,
    4. Bacon PA

    . Disease assessment and management of the vasculitides. Baillieres Clin Rheumatol 1997;11:423–46.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Exley AR,
    2. Bacon PA,
    3. Luqmani RA,
    4. Kitas GD,
    5. Gordon C,
    6. Savage CO,
    7. et al.

    Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371–80.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Suppiah R,
    2. Flossmann O,
    3. Mukhtyar C,
    4. Alberici F,
    5. Baslund B,
    6. Brown D,
    7. et al.

    Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. Ann Rheum Dis 2011;70:80–5.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Seo P,
    2. Merkel PA,
    3. Specks U,
    4. Hoffman GS,
    5. Langford CA,
    6. Spiera R,
    7. et al.

    Damage in ANCA-associated vasculitis: Preliminary evidence for the ANCA-associated Vasculitis Index of Damage [abstract]. Arthritis Rheum 2006;54 Suppl:S487.

    OpenUrl
23. 23.↵
    1. Seo P,
    2. Silva F,
    3. Hoffman GS,
    4. Spiera R,
    5. Davis JC,
    6. McCune WJ,
    7. et al.

    Morbidity and mortality of Wegener’s granulomatosis: Data from a current multicenter longitudinal cohort [abstract]. Arthritis Rheum 2008;58 Suppl:S852–3.

    OpenUrl
24. 24.↵
    1. Luqmani R,
    2. Suppiah R,
    3. Edwards CJ,
    4. Phillip R,
    5. Maskell J,
    6. Culliford D,
    7. et al.

    Mortality in Wegener’s granulomatosis: a bimodal pattern. Rheumatology 2011;50:697–702.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Flossmann O,
    2. Berden A,
    3. De Groot K,
    4. Hagen C,
    5. Harper L,
    6. Heijl C,
    7. et al.

    Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70:488–94.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    1. Herlyn K,
    2. Hellmich B,
    3. Seo P,
    4. Merkel PA

    . Patient-reported outcome assessment in vasculitis provides important data and a unique perspective. Arthritis Care Res (Hoboken) 2010;62:1639–45.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Seo P,
    2. Jayne D,
    3. Luqmani R,
    4. Merkel PA

    . Assessment of damage in vasculitis: expert ratings of damage. Rheumatology 2009;48:823–7.

    OpenUrlAbstract/FREE Full Text
28. 28.↵
    1. Neogi T,
    2. Xie H,
    3. Felson DT

    . Relative responsiveness of physician/assessor-derived and patient-derived core set measures in rheumatoid arthritis trials. J Rheumatol 2008;35:757–62.

    OpenUrlAbstract/FREE Full Text
29. 29.↵
    1. McHorney CA,
    2. Ware JE Jr.,
    3. Lu JF,
    4. Sherbourne CD

    . The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40–66.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. McHorney CA,
    2. Ware JE Jr.,
    3. Rogers W,
    4. Raczek AE,
    5. Lu JF

    . The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study. Med Care 1992;30 Suppl:MS253–65.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Koutantji M,
    2. Harrold E,
    3. Lane SE,
    4. Pearce S,
    5. Watts RA,
    6. Scott DG

    . Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis. Arthritis Rheum 2003;49:826–37.

    OpenUrlCrossRefPubMed
32. 32.↵
    1. Newall C,
    2. Schinke S,
    3. Savage CO,
    4. Hill S,
    5. Harper L

    . Impairment of lung function, health status and functional capacity in patients with ANCA-associated vasculitis. Rheumatology 2005;44:623–8.

    OpenUrlAbstract/FREE Full Text
33. 33.↵
    1. Srouji IA,
    2. Andrews P,
    3. Edwards C,
    4. Lund VJ

    . General and rhinosinusitis-related quality of life in patients with Wegener’s granulomatosis. Laryngoscope 2006;116:1621–5.

    OpenUrlCrossRefPubMed
34. 34.↵
    1. Walsh M,
    2. Mukhtyar C,
    3. Mahr A,
    4. Herlyn K,
    5. Luqmani R,
    6. Merkel PA,
    7. et al.

    Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res 2011 Mar 30 [Epub ahead of print].
35. 35.↵
    1. Tomasson G,
    2. Boers M,
    3. Walsh M,
    4. Cuthbertson D,
    5. Carette S,
    6. Davis JC,
    7. et al.

    Measurement of health-related quality of life among patients with ANCA-associated vasculitis using the SF-36. (submitted).